Online citations, reference lists, and bibliographies.
← Back to Search

Current Best Practice In The Evaluation And Management Of Malignant Pleural Effusions

S. Walker, A. Bibby, N. Maskell
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural effusions (MPEs) are an important cause of cancer-related mortality and morbidity. It is a heterogeneous group of conditions, which leads to debilitating symptoms and confers a poor prognosis. Recent well-designed randomized trials have provided a broader evidence base for an expanding range of treatment options. Together, with new prognostic scoring systems and a greater understanding of how different patient phenotypes respond to treatment, this allows greater personalization of management. This article will discuss the current evidence on evaluation and management of MPEs.
This paper references
10.1186/s13063-015-0563-y
The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial
R. Bhatnagar (2015)
The minimum fluid volume adequacy to diagnose malignant pleural effusion: a retrospective study
R. Khosla (2016)
10.1055/S-2007-1012685
Invasive Procedures in the Diagnosis of Pleural Disease
J. R. Tomlinson (1987)
10.1158/1078-0432.CCR-10-2245
High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
S. Kao (2010)
10.1136/thx.2010.136994
Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010
M. Roberts (2010)
10.1097/LBR.0000000000000001
Infections Associated With Tunnelled Indwelling Pleural Catheters in Patients Undergoing Chemotherapy
E. Mekhaiel (2013)
10.1183/16000617.0019-2016
Malignant pleural effusion: from bench to bedside
I. Psallidas (2016)
Relationship between
E. Bedel (2009)
10.1378/CHEST.117.1.79
Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions.
J. Heffner (2000)
10.1001/jama.2015.16840
Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial.
N. Rahman (2015)
10.1038/mt.2009.309
A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-β Gene Transfer for Mesothelioma and Metastatic Pleural Effusions.
D. Sterman (2010)
10.1148/radiol.12110872
Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging--initial experience.
J. Coolen (2012)
10.1097/JTO.0b013e318189f53d
Diagnostic and Prognostic Implications of Pleural Adhesions in Malignant Effusions
S. Bielsa (2008)
The Third Therapeutic Intervention In Malignant Effusion Trial (time3): A Randomised Controlled Trial To Assess Dyspnea Relief And Pleurodesis Success Following Intrapleural Urokinase In Patients With Non-Draining Malignant Pleural Effusion
E. Mishra (2016)
10.2217/fon.11.45
Diagnostic molecular biomarkers for malignant pleural effusions.
K. Sriram (2011)
2016) Australasian Malignant Pleural Effusion (AMPLE) Trial: a multicentre randomised study comparing indwelling pleural catheter versus talc pleurodesis
Y. Lee (2016)
10.1007/s11606-010-1472-0
Efficacy and Safety of Tunneled Pleural Catheters in Adults with Malignant Pleural Effusions: A Systematic Review
Margaret E. M. Van Meter (2010)
10.1097/00004728-198907000-00011
MR Imaging of Malignant Pleural Mesothelioma
J. Lorigan (1989)
10.1183/09031936.00164706
Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis
A. Tremblay (2007)
10.1308/003588408X318246
Diagnostic and therapeutic performance of video-assisted thoracoscopic surgery (VATS) in investigation and management of pleural exudates.
A. Medford (2008)
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune
D. Sterman (2007)
10.1136/thx.2010.137018
Local anaesthetic thoracoscopy: British Thoracic Society pleural disease guideline 2010
N. Rahman (2010)
10.4065/83.2.235
Recent advances in the diagnosis and management of malignant pleural effusions.
J. Heffner (2008)
10.1378/chest.09-0641
Prospective study to determine the volume of pleural fluid required to diagnose malignancy.
J. Swiderek (2010)
10.1378/CHEST.104.6.1763
A comparison of rotation and nonrotation in tetracycline pleurodesis.
S. R. Dryzer (1993)
10.1136/thx.2008.100545
Thoracic ultrasound in the diagnosis of malignant pleural effusion
N. R. Qureshi (2008)
10.1016/S0140-6736(14)60418-9
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial
R. Rintoul (2014)
10.1378/chest.14-0820
Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis.
J. M. Porcel (2015)
10.1001/jama.2012.5535
Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial.
H. E. Davies (2012)
10.1378/chest.09-1044
The relationship between chest tube size and clinical outcome in pleural infection.
N. Rahman (2010)
10.1097/MCP.0000000000000267
Phenotyping malignant pleural effusions
M. M. S. Lui (2016)
10.1038/mt.2009.309
A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions.
D. Sterman (2010)
10.1148/radiol.12112077
Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy.
L. Sconfienza (2013)
10.1136/bmjopen-2013-004145
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
10.1097/MCP.0000000000000258
Pleural biopsies in undiagnosed pleural effusions; Abrams vs image-guided vs thoracoscopic biopsies
A. Bibby (2016)
10.1016/j.ccm.2012.11.002
Pleural fluid biomarkers: beyond the Light criteria.
J. M. Porcel (2013)
10.1155/2014/413946
Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
J. Creaney (2014)
10.1378/chest.14-0299
Physician-based ultrasound-guided biopsy for diagnosing pleural disease.
R. Hallifax (2014)
10.1378/CHEST.126.6.1757
Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
J. M. Porcel (2004)
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma
R. Rintoul (2014)
Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium.
K. Chang (1992)
Malignant pleural disease: diagnosis
J. Coolen (2012)
10.1136/thoraxjnl-2014-206676
Ultrasound-guided pneumothorax induction prior to local anaesthetic thoracoscopy
J. Corcoran (2015)
The minimum fluid volume adequacy to diagnose malignant pleural effusion : a retrospective study . B 36 . Pleural Disease : Clinical Studies ( American Thoracic Society )
E. Fysh (2016)
10.1002/jcu.20884
Ultrasonography guidance reduces complications and costs associated with thoracentesis procedures
P. Patel (2012)
10.1111/resp.12328
Interventional therapies for malignant pleural effusions: The present and the future
Rajesh Thomas (2014)
10.1378/chest.14-1701
Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion.
E. Fysh (2015)
10.1136/thx.2010.136978
Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010
C. Hooper (2010)
10.1016/J.CCM.2006.02.001
Imaging of pleural disease.
N. R. Qureshi (2006)
10.1016/S0169-5002(01)00475-5
Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis.
Hans-Jurgen Mager (2002)
10.1378/CHEST.107.5.1454
Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion.
D. Waller (1995)
10.1378/chest.14-2401
Intrapleural Fibrinolysis for the Treatment of Indwelling Pleural Catheter-Related Symptomatic Loculations: A Multicenter Observational Study.
Rajesh Thomas (2015)
10.1016/S0140-6736(03)13079-6
Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial
N. Maskell (2003)
10.2214/AJR.154.3.2106209
CT in differential diagnosis of diffuse pleural disease.
A. Leung (1990)
10.1159/000360769
Indwelling Pleural Catheters
R. Bhatnagar (2014)
10.1136/thoraxjnl-2014-205285
Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score
A. Clive (2014)
10.1258/000456307781645978
Biochemical analysis of pleural and ascitic fluid: effect of sample timing on interpretation of results
F. Jenkinson (2007)
10.1001/jama.2012.5543
Treatment options for malignant pleural effusions: patient preference does matter.
N. Maskell (2012)
10.1378/CHEST.117.1.73
Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease.
C. Burrows (2000)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
[Pleural effusions].
G. Pescetti (1965)
10.1378/chest.09-0884
Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial.
M. Metintas (2010)
10.1378/chest.12-3103
Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study.
E. Fysh (2013)
10.1182/BLOOD.V120.21.4891.4891
Malignant Pleural Effusion and Advanced Stage Low-Grade Non-Hodgkin's Lymphoma Successfully Treated with Intrapleural Instillation of Rituximab
A. Islam (2012)
10.1158/1078-0432.CCR-07-0403
A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses
D. Sterman (2007)
A phase I clinical trial of single - dose intrapleural IFN - beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions : high rate of antitumor immune responses
D. Sterman (2010)
10.1016/S1470-2045(16)30095-X
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
A. Clive (2016)
10.1002/14651858.CD010529.pub2
Interventions for the management of malignant pleural effusions: a network meta-analysis.
A. Clive (2016)
10.1136/bmjresp-2015-000123
Complications of indwelling pleural catheter use and their management
M. M. S. Lui (2016)
10.1097/01.rli.0000131888.39636.c5
Asbestos-Related Pleural Disease: Value of Dedicated Magnetic Resonance Imaging Techniques
M. Weber (2004)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1183/09031936.00069812
Survival of lung adenocarcinoma patients with malignant pleural effusion
S. Wu (2012)
10.1183/16000617.0020-2016
Advanced medical interventions in pleural disease
R. Bhatnagar (2016)
10.1016/j.rmed.2012.04.009
Outcome of patients diagnosed with fibrinous pleuritis after medical thoracoscopy.
M. Metintas (2012)
10.1186/s12890-016-0203-7
Safety of indwelling pleural catheter use in patients undergoing chemotherapy: a five-year retrospective evaluation
C. Chan Wah Hak (2016)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar